<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423370</url>
  </required_header>
  <id_info>
    <org_study_id>YHD1023-201</org_study_id>
    <nct_id>NCT01423370</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of YHD1023 in Erectile Dysfunction</brief_title>
  <official_title>Multi-center, Randomized, Double-blind, Placebo/Active-controlled, Phase II Clinical Trial to Assess the Safety and Efficacy of YHD1023 in Patients With Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and efficacy of oral YHD1023 5g or 10g on
      erectile dysfunction to investigate the optimal recommended dosage. Study period is 12 weeks
      including 4weeks of follow-up period without treatment. Study patients will fill in the
      international index of erectile function questionnaire and life satisfaction questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the International Index of Erectile Function(IIEF) - Erectile Function(EF) domain score at week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Improved patients from baseline in Question 3 &amp; Question 4 of the International Index of Erectile Function(IIEF) at week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>*Improved: Score increased 1 or more compared to the baseline score
Question 3: How many times were you able to insert your penis into your partner's vagina? Scores range from 0(did not have sexual intercourse) to 5(always or most times).
Question 4: How many times did your erection last long enough for you to complete intercourse? Scores range from 0(did not have sexual intercourse) to 5(always or most times).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in other Question of International Index of Erectile Function(IIEF) domain at week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Improved patients from baseline in Question 2 &amp; Question 3 of Sexual Encounter Profile(SEP) at week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>*Improved: Response change from &quot;No&quot; at baseline to &quot;Yes&quot; at week 8
Question 2: Were you able to insert your penis into your partner's vagina?
Question 3: Did your erection last long enough for you to complete intercourse with ejaculation?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Improved patients from baseline in Global Assessment Question(GAQ) at week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>*Improved: Yes response at week 8
GAQ: Did the 4 week treatment improve you ability to achieve and maintain your erection?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Life Satisfaction score</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD1023</intervention_name>
    <description>5g oral once daily</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD1023</intervention_name>
    <description>5g oral twice a day</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YHD1023</intervention_name>
    <description>10g oral once daily</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cialis</intervention_name>
    <description>5mg oral once daily</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male volunteers of aged 20 years and older with history of organic erectile
             dysfunction of at least 6 months duration

          -  Anticipate having the same adult female sexual partner, who have no possibility of
             being pregnant or breast-feeding and take steps to prevent conception during the study

          -  The patient or legally authorized representative must sign a written informed consent,
             prior to the any procedure, using a form that is approved by the local Institutional
             Review Board after detail explanation of the purpose, contents, and characteristic of
             the drug

          -  Have Erectile Function(EF) domain score 25 and under as the result of the
             International Index of Erectile Function(IIEF)

          -  Agree to make at least 4 sexual intercourse attempts on 4 separate days with the
             female sexual study party during the 4-week run-in period without medication and at
             least 50% of attempts during this period had been unsuccessful due to insufficient
             erection or unable to sustain penile rigidity until ejaculation

        Exclusion Criteria:

          -  Have history of stroke, myocardial infarction, or Coronary Artery Bypass Graft surgery
             within the last 6 months

          -  Have history of cardiac failure, unstable angina, or life-threatening arrhythmia
             within the last 6 months

          -  Shown tachyarrhythmia, heart rate over 100 times/min(e.g. arterial fibrillation,
             flutter)

          -  Presence of hypotension as evidenced by SBP/DBP &lt; 90/50mmHg or uncontrollable
             hypertension as evidenced by SBP/DBP &gt; 170/100mmHg

          -  Presence of diagnosed diabetes(HbA1C &gt; 12%)

          -  Have history of symptomatic postural hypotension within the last 6 months

          -  Have history of spinal cord injury, radical prostatectomy, or pelvic surgery

          -  Presence of penile anatomical deformities (e.g. severe penile fibrosis or Peyronie's
             disease)

          -  Presence of hypogonadism(serum total testosterone under the reference lowest limit)

          -  Presence of hepatic impairment(AST or ALT &gt; 3 times of normal upper limit) or renal
             impairment(serum creatinine â‰¥ 2.5mg/dl)

          -  Have history of severe gastrointestinal hemorrhage within the last 1 year

          -  Have history of hematodyscrasia predisposing to priapism(e.g. sickle cell disease,
             multiple myeloma, or leukemia) or bleeding disorder

          -  Subject who is judged to be ineligible according to their physical checkup(medical
             history, physical examination, ECG, laboratory values and etc.) within 56 days prior
             to the first administration

          -  Concomitant use of one or more of nitrates/nitric oxide(NO) donor(e.g. nitroglycerine,
             isosorbid, mononitrate, isosorbid dinitrate, amylnitrate/nitrite, sodium
             nitroprusside), Trazodone, cancer chemotherapy, anticoagulants, androgens, or
             anti-androgens

          -  Use of any PDE-5 inhibitor(e.g. Viagra, Levitra, Cialis, Yaila, or Zydena),
             vasodilator self-injection, or other treatments for erectile dysfunction within the
             last 2 weeks prior to the study

          -  Participated in any other clinical trials within 30 days prior to the first
             administration

          -  Have history of primary hypoactive sexual desire

          -  Subject who is judged to be ineligible by principal investigator or sub-investigator
             due to mental disorder or continuous drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nam-Cheol Park, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Busan National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yuhan Corporation</name>
      <address>
        <city>Seoul</city>
        <zip>156-754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <last_update_submitted>July 30, 2014</last_update_submitted>
  <last_update_submitted_qc>July 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>YHD1023</keyword>
  <keyword>YCD190</keyword>
  <keyword>Cialis</keyword>
  <keyword>Yuhan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

